Optomed
4.945 EUR +6.8%5,070 investors are following this company
Optomed is a medical technology company. The company conducts research and development of specialized eye cameras. Development takes place of both hardware and software that is resold under different brands. The company operates worldwide, with the largest presence in the Nordic market. The customers consist of research institutes and hospitals. Optomed is headquartered in Oulu.
P/E (24e)
-18.99
EV/EBIT (adj.) (24e)
-18.61
P/B (24e)
5.59
Dividend yield-% (24e)
-
Target price
4.50 EUR
Recommendation
Reduce
Updated
1.5.2024
NASDAQ Helsinki
OPTOMED
Daily low / high price
4.59 / 5.05
EUR
Market cap
89.65M EUR
Turnover
2.01M EUR
Volume
425K
Business risk
Valuation risk
Current
Previous
Analyst
Juha Kinnunen
Analyst
Latest videos
Financial calendar
Interim report
07.05.2024
General meeting
10.05.2024
Interim report
08.08.2024
Interim report
07.11.2024
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Skandinaviska Enskilda Banken Ab (publ) Helsinki Branch | 8.2 % | 8.2 % |
OP-Finland Small Cap | 7.9 % | 7.9 % |
Premium
This content is for our Premium customers only.
Insider Transactions
Insider | Date | Total value |
---|---|---|
Juho-pekka Himberg | 05.03.2024 | 114,114EUR |
Reijo Tauriainen | 06.05.2022 | 11,365EUR |
Premium
This content is for our Premium customers only.
Income statement
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
Revenue | 13.0 | 14.9 | 14.7 | 15.1 | 16.5 | 23.3 | 29.8 | 37.8 |
growth-% | -13.1 % | 14.1 % | -1.3 % | 3.0 % | 9.2 % | 41.2 % | 28.1 % | 26.8 % |
EBITDA | -0.7 | -2.0 | -2.0 | -1.8 | -2.5 | -0.1 | 2.9 | 6.6 |
EBIT (adj.) | -2.9 | -4.8 | -5.1 | -3.7 | -4.8 | -2.6 | 0.3 | 3.9 |
EBIT | -2.9 | -4.8 | -5.1 | -4.0 | -4.8 | -2.6 | 0.3 | 3.9 |
Profit before taxes | -3.2 | -4.3 | -5.6 | -4.5 | -4.6 | -3.0 | -0.1 | 3.6 |
Net income | -3.2 | -4.2 | -5.5 | -4.4 | -4.6 | -3.0 | -0.1 | 3.6 |
EPS (adj.) | -0.24 | -0.31 | -0.38 | -0.25 | -0.26 | -0.17 | -0.01 | 0.20 |
growth-% | ||||||||
Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.10 |
Dividend ratio | 50.0 % |
Profitability and return on capital
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
EBITDA-% | -5.6 % | -13.5 % | -13.3 % | -11.8 % | -15.2 % | -0.5 % | 9.8 % | 17.4 % |
EBIT-% (adj.) | -22.3 % | -32.2 % | -34.8 % | -24.3 % | -29.0 % | -11.2 % | 0.9 % | 10.4 % |
EBIT-% | -22.3 % | -32.2 % | -34.8 % | -26.3 % | -29.0 % | -11.2 % | 0.9 % | 10.4 % |
ROE | -14.9 % | -22.9 % | -29.3 % | -21.8 % | -25.6 % | -20.8 % | -1.0 % | 24.6 % |
ROI | -9.8 % | -18.9 % | -20.5 % | -15.5 % | -20.5 % | -11.7 % | 1.6 % | 16.6 % |
Valuation
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
Share price (EUR) | 7.22 | 9.80 | 3.75 | 3.72 | 4.95 | 4.95 | 4.95 | 4.95 |
Shares | 13.3 | 13.6 | 16.2 | 17.8 | 17.8 | 17.8 | 17.8 | 17.8 |
Market cap | 95.8 | 133.1 | 60.5 | 66.0 | 87.9 | 87.9 | 87.9 | 87.9 |
Enterprise value | 91.7 | 133.3 | 57.3 | 62.3 | 88.9 | 92.6 | 93.4 | 91.4 |
EV/S | 7.0 | 9.0 | 3.9 | 4.1 | 5.4 | 4.0 | 3.1 | 2.4 |
EV/EBITDA | - | - | - | - | - | - | 32.1 | 13.9 |
EV/EBIT (adj.) | - | - | - | - | - | - | 355.3 | 23.2 |
EV/EBIT | - | - | - | - | - | - | 355.3 | 23.2 |
P/E (adj.) | - | - | - | - | - | - | - | 24.7 |
P/E | - | - | - | - | - | - | - | 24.7 |
P/B | 4.8 | 7.8 | 3.0 | 3.2 | 5.6 | 6.9 | 7.0 | 5.4 |
P/S | 7.4 | 9.0 | 4.1 | 4.4 | 5.3 | 3.8 | 2.9 | 2.3 |
Dividend yield | 2.0 % | |||||||
Equity ratio | 64.6 % | 58.8 % | 65.0 % | 70.0 % | 57.5 % | 44.7 % | 40.0 % | 45.0 % |
Gearing ratio | -20.4 % | 1.2 % | -16.0 % | -18.5 % | 6.6 % | 36.6 % | 43.7 % | 21.4 % |
Quarter data
Q1/23 | Q2/23 | Q3/23 | Q4/23 | 2023 | Q1/24e | Q2/24e | Q3/24e | Q4/24e | |
---|---|---|---|---|---|---|---|---|---|
Revenue | 3.5 | 3.7 | 4.2 | 3.7 | 15.1 | 3.7 | 4.0 | 4.1 | 4.8 |
EBITDA | -0.5 | -0.5 | -0.0 | -0.8 | -1.8 | -0.5 | -0.4 | -0.8 | -0.8 |
EBIT | -1.0 | -1.0 | -0.6 | -1.3 | -4.0 | -1.1 | -1.0 | -1.3 | -1.4 |
Profit before taxes | -1.2 | -1.3 | -0.5 | -1.5 | -4.5 | -1.0 | -0.9 | -1.3 | -1.4 |
Net income | -1.2 | -1.3 | -0.4 | -1.5 | -4.4 | -1.0 | -0.9 | -1.3 | -1.4 |
ShowingAll content types
Optomed Oyj: No updates on the Optomed Aurora AEYE FDA clearance process
Optomed Oyj: Notice of the Annual General Meeting of Optomed Plc
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools